Kaitlyn M Logan, Will Kaplan, Vladimir Simov, Hua Zhou, Derun Li, Luis Torres, Gregori J Morriello, John J Acton, Barbara Pio, Yi-Heng Chen, Mitchell H Keylor, Rebecca Johnson, Solomon D Kattar, Ryan Chau, Xin Yan, Michael Ardolino, Cayetana Zarate, Karin M Otte, Rachel L Palte, Tina Xiong, Spencer E McMinn, Shishi Lin, Santhosh F Neelamkavil, Ping Liu, Jing Su, Laxminarayan G Hegde, Janice D Woodhouse, Lily Y Moy, Paul J Ciaccio, Jennifer Piesvaux, Matthias Zebisch, Clare Henry, John Barker, Harold B Wood, Matthew E Kennedy, Erin F DiMauro, Matthew J Fell, Peter H Fuller
Inhibition of leucine-rich repeat kinase 2 is a genetically supported mechanism for the treatment of Parkinson's disease. We previously disclosed the discovery of an indazole series lead that demonstrated both safety and translational risks. The safety risks were hypothesized to be of unknown origin, so structural diversity in subsequent chemical matter was prioritized. The translational risks were identified due to a low brain Kpu,u in nonhuman primate studies, which raised concern over the use of an established peripheral biomarker as a surrogate for central target engagement...
September 4, 2024: Journal of Medicinal Chemistry